Upper Respiratory Tract Infection Treatment Market to Reach USD 30.37 Billion by 2035

According to analysts at Vantage Market Research, the Global Upper Respiratory Tract Infection Treatment Market size is worth USD 15.67 Billion in 2024 and is projected to reach USD 30.37 Billion by 2035, growing at a CAGR (Compound Annual Growth Rate) of 6.20% from 2024 to 2035. The market key trends are growing demand for OTC and natural remedies, advancements in rapid diagnostics, increasing focus on vaccinations, telemedicine adoption, antimicrobial stewardship, and targeted treatments for vulnerable populations.

Market Overview

Advancements in diagnostic tools are significantly driving the Upper Respiratory Tract Infection Treatment market by enabling faster, more accurate, and efficient identification of infection-causing agents. Technologies such as rapid antigen tests (RATs), polymerase chain reaction (PCR) assays, and multiplex assays provide results within minutes to hours, helping distinguish between viral and bacterial URTIs to guide appropriate treatments and reduce unnecessary antibiotic use. Point-of-care (POC) devices have further enhanced accessibility by allowing quick diagnostics in outpatient settings or even at home, while advanced molecular techniques like next-generation sequencing (NGS) and microarray technology enable comprehensive pathogen detection, including in cases of co-infection.

The high prevalence of upper respiratory tract infections (URTIs) is a key driver in the URTI treatment market, significantly impacting the demand for therapeutic and preventive solutions. URTIs, including the common cold, sinusitis, pharyngitis, and laryngitis, are among the most widespread infectious diseases globally, affecting individuals across all age groups. Their high incidence is attributed to factors such as seasonal changes, increasing air pollution, crowded living conditions, and the ease of transmission of viral and bacterial pathogens through respiratory droplets.

Novartis receives FDA approval for Fabhalta® (iptacopan), offering superior hemoglobin improvement in the absence of transfusions as the first oral monotherapy for adults with PNH

• In December 2023, Novartis announced that the U.S. Food and Drug Administration (FDA) approved Fabhalta® (iptacopan) as the first oral monotherapy for the treatment of adults with paroxysmal nocturnal hemoglobinuria (PNH)1. Fabhalta is a Factor B inhibitor that acts proximally in the alternative complement pathway of the immune system, providing comprehensive control of red blood cell (RBC) destruction within and outside the blood vessels (intra- and extravascular hemolysis [IVH and EVH]). In clinical trials, treatment with Fabhalta increased hemoglobin levels (≥ 2 g/dL from baseline in the absence of RBC transfusions) in the majority of patients and in APPLY-PNH nearly all patients treated with Fabhalta did not receive blood transfusions

Key Takeaways from the Report

• In 2024, North America dominated the market with largest market share of 47.60%. The Market is driven by growing healthcare needs of the aging population, increasing awareness about treatment options, and advancements in medical technology and pharmaceuticals
• Based on the Treatment Type, the Drug treatment category accounted for significant market share of 58.90% in 2024. The segment is driven by high incidence of URTIs, particularly during cold and flu seasons, as well as increasing consumer awareness of available treatments
• In 2024, based on the Distribution Channel, the hospital pharmacies category holds the largest market share. Hospital pharmacies provide a broader range of prescription-based treatments and specialized care options for patients requiring more intensive management

Top Companies

• Pfizer Inc
• Merck & Co. Ltd.
• Alcon Ltd
• Teva Pharmaceuticals
• Hospira Inc
• Verona Pharma
• Sandoz Inc
• Sun Pharmaceuticals Industries
• Cipla
• Reddy’s Laboratories
• Sanofi Inc

Report Coverage

Our market research reports provide comprehensive insights that are essential for strategic decision-making. We cover all key aspects of the market, including dynamics such as drivers, restraints, opportunities, and challenges, alongside the latest industry trends. Our analysis includes an in-depth technology roadmap, product life cycle evaluation, and PESTLE analysis, ensuring a thorough understanding of the market environment. We also assess GDP growth outlooks, examine regional market landscapes, and evaluate the impact of major events like the COVID-19 pandemic. Additionally, our reports feature a detailed competitive landscape, including company market shares and profiles, providing actionable intelligence to empower your business strategies.

Latest News

Merck’s Clesrovimab (MK-1654), an Investigational Respiratory Syncytial Virus (RSV) Preventative Monoclonal Antibody, Significantly Reduced Incidence of RSV Disease and Hospitalization in Healthy Preterm and Full-term Infants

• In October 2024, Merck known as MSD outside of the United States and Canada, today announced the presentation of positive results from the Phase 2b/3 clinical trial (MK-1654-004) evaluating clesrovimab, the company’s investigational prophylactic monoclonal antibody designed to protect infants from respiratory syncytial virus (RSV) disease during their first RSV season. The results, along with interim findings from the ongoing Phase 3 trial (MK-1654-007) of clesrovimab, were presented during IDWeek 2024, held October 16-19 in Los Angeles, California